July - September 2024, Volume 20, Issue 3

Demir SB, Yesilova A, Cengiz M, Adas M

Current Treatment Approaches and Glycemic Control in Turkish Patients with Type 2 Diabetes Mellitus: A Real-World Evidence from a Tertiary Hospital in Turkey

Acta Endo (Buc) 2024, 20 (3): 324-333
doi: 10.4183/aeb.2024.324

Objective. This study examined the glycemic control among adult patients with type 2 diabetes mellitus (T2DM) and their ongoing antidiabetic therapy focusing on potential differences in attaintment of glycemic control associated with the use of specific antidiabetic regimens (ADR). Design. This was a cross sectional study conducted between September 2019 and March 2020 at a tertiary hospital, department of Internal Medicine. Subjects and Methods. Patients with T2DM who had a diagnosis of T2DM for at least one year and used their prescribed ADR for at least 3 months were included in the study. Glycated hemoglobin (HbA1c) was used for evaluation of glycemic control. Results. A total of 500 patients aged 59.4 (±10.2) years, with 9.9 (±6.7) years of diabetes duration (54% women, BMI: 29.6±5.1kg/m2) were analysed. The mean HbA1c was 8.3% (±1.9) and 34.2% of patients had a HbA1c level ≤7 %. 12%, 20% and 15.4% of diabetic patients were prescribed one, two or more than three antidiabetic drugs, 6.4% were on glucagon-like peptide 1 receptor agonists (GLP-1RA) only and 46% received insulin. Education level (OR=0.79; 95 % CI 0.66-0.94 p=0.009) and use of GLP-1RA (OR=0.19; 95 % CI 0.07-0.51 p=0.001) were associated with improved glycemic control while longer diabetes duration (OR=1.06; 95 % CI 1.02-1.11 p=0.004), use of basal insulin (OR=2.91; 95 % CI 1.70-6.88 p=0.010) and basal-prandial regiments (OR=2.49; CI 1.54-5.38 p=0.020) were associated with HbA1c >7%. Conclusions. Despite the introduction of novel drugs in the treatment of T2DM a majority of our patients fail to reach therapeutic goals.

Keywords: Type 2 diabetes mellitus, HbA1c, glycemic control, oral antidiabetic treatment, insulin.

Correspondence: Aylia Yesilova, Health Sciences University, Istanbul Prof. Dr. Cemil Tascioglu City Hospital, Department of Internal Medicine, Istanbul, Turkey, E-mail: yesilovaay@yahoo.com